Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients during Lamivudine plus Dolutegravir Maintenance Therapy in Clinical Practice

Simona Di Giambenedetto, Alberto Borghetti, Alex Dusina

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

The TANGO trial demonstrated the efficacy of lamivudine plus dolutegravir in virologically suppressed patients without previous virological failures (VFs). In this dataset from clinical practice investigating the impact of past nucleoside reverse-transcriptase inhibitor resistance on this strategy, the combination of M184V/I plus at least 1 thymidine analog-associated mutation significantly increased the risk of VF.
Lingua originaleEnglish
pagine (da-a)ofab103-ofab103
RivistaOpen Forum Infectious Diseases
Volume8
DOI
Stato di pubblicazionePubblicato - 2021

Keywords

  • dolutegravir
  • HIV
  • resistance-associated mutations
  • maintenance therapy
  • lamivudine

Fingerprint

Entra nei temi di ricerca di 'Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients during Lamivudine plus Dolutegravir Maintenance Therapy in Clinical Practice'. Insieme formano una fingerprint unica.

Cita questo